Global Cardiac Biomarkers Testing Market was valued at USD 3.50 billion in 2021, growing at a CAGR of 7.77% during the forecast period from 2022 to 2027 to reach USD 5.48 billion by 2027. Factors such as the increasing prevalence of cardiovascular diseases, the growing need for early diseases diagnosis, rising aging population, and the advancement in research in identifying novel clinically-relevant cardiac biomarkers are stimulating the growth of the cardiac biomarker testing market positively.
Some of the key market players operating in the Cardiac Biomakers Testing Devices market include Beckman Coulter, Inc, Siemens Healthcare GmbH, Abbott, bioMérieux SA, F. Hoffmann-La Roche Ltd, Thermo Fischer Scientific Inc, Bio-Rad Laboratories Inc, Eurolyser Diagnostica GmbH, Diagnostic Automation / Cortez Diagnostics, Inc, Randox Laboratories Ltd, Tosoh Corporation, DIALAB GmbH, CardioGenics Holdings Inc, Lepu Medical Technology (Beijing) Co. Ltd., Biosynex and others.
DelveInsight’s “Cardiac Biomakers Testing Devices Market Share & Forecast” report will offer an in-depth understanding of the Cardiac Biomakers Testing Devices market, further benefiting the competitors or stakeholders operating in the Cardiac Biomakers Testing Devices arena.
Cardiac biomarkers are protein molecules that are released into the blood after heart damage or heart-stress. These biomarkers act as a potential tool in the detection and diagnosis of various cardiovascular diseases.
Interested to know more about the functioning of Cardiac biomarkers testing devices:- Cardiac Biomakers Testing Devices Market Share
- In April 2021, Roche announced the series of five new intended uses for two key cardiac biomarkers using the Elecsys® technology: high sensitive cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide test (NT-proBNP).
- In 2019, Roche Diagnostics launched the VITROS high-sensitivity Troponin I assay
According to DelveInsight, the Cardiac Biomarkers Testing Devices Clinical Development market would rise rapidly throughout the forecast period due to continuous commercial and clinical development.
In the global market for cardiac biomakers testing device key players contribute significantly to their development and are also active in mergers and acquisitions to strengthen their market position.
Some of the Cardiac Biomakers Testing Device Companies operating actively in the Cardiac Biomakers Testing Device include Beckman Coulter, Inc, Siemens Healthcare GmbH, Abbott, bioMérieux SA, F. Hoffmann-La Roche Ltd, Thermo Fischer Scientific Inc, Bio-Rad Laboratories Inc, Eurolyser Diagnostica GmbH, Diagnostic Automation / Cortez Diagnostics, Inc, Randox Laboratories Ltd, Tosoh Corporation, DIALAB GmbH, CardioGenics Holdings Inc, Lepu Medical Technology (Beijing) Co. Ltd., Biosynex and others.
Learn more about the Cardiac Biomakers Testing Device, and get in-depth information at Cardiac Biomakers Testing Devices Market Size
- Study Period- 2019-2027
- Key Cardiac Biomakers Testing Devices Companies– Beckman Coulter Inc, Siemens Healthcare GmbH (NYSE: SHL), Abbott (NYSE: ABT), bioMérieux SA (NYSE: BMXMF), F. Hoffmann-La Roche Ltd (NYSE: ROG.SW), Thermo Fischer Scientific Inc (NYSE: TMO), Bio-Rad Laboratories Inc (NYSE: BIO), Eurolyser Diagnostica GmbH, Diagnostic Automation / Cortez Diagnostics, Inc, Randox Laboratories Ltd, Tosoh Corporation, DIALAB GmbH, CardioGenics Holdings Inc (NYSE: CGNH), Lepu Medical Technology (Beijing) Co. Ltd., Biosynex, and several others.
- Cardiac Biomarker Testing Market by Product Type (Instruments And Reagents & Kits),
- Cardiac Biomarker Testing Market By Biomarker Type (Troponin, Creatine Kinase-MB, Natriuretic Peptide, Myoglobin, and Others]),
- Cardiac Biomarker Testing Market By Application (Acute Coronary Syndrome, Congestive Heart Failure, Myocardial Infarction, and Others)
- By End User (Hospitals, Pathology Labs, And Others), and
- By Geography (North America, Europe, Asia-Pacific, and Rest of the World).
- Porter’s Five Forces Analysis, Product Profiles, Cases Studies, KOL’s Views, and Analyst’s View
Table of Content
- Cardiac Biomarker Testing Market Report Introduction
- Cardiac Biomarker Testing Market Executive Summary
- Regulatory and Patent Analysis
- Cardiac Biomarker Testing Market Key Factors Analysis
- Cardiac Biomarker Testing Market Porter’s Five Forces Analysis
- COVID-19 Impact Analysis on Cardiac Biomarker Testing Market
- Cardiac Biomarker Testing Market Layout
- Cardiac Biomarker Testing Market Global Company Share Analysis – Key 3-5 Companies
- Cardiac Biomarker Testing Market Company and Product Profiles
- Project Approach
- KOL Views
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
For more details about the market share of Cardiac Biomakers Testing Devices, just click here @ Cardiac Biomakers Testing Devices Companies
- Market size analysis for cardiac biomarker testing market size (2021), and market forecast for 5 years (2022-2027)
- The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the cardiac biomarker testing market.
- Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
- Key companies dominating the global cardiac biomarker testing market.
- Various opportunities available for the other competitor in the cardiac biomarker testing market space.
- What are the top performing segments in 2021? How these segments will perform in 2027.
- Which is the top-performing regions and countries in the current cardiac biomarker testing market scenario?
- Which are the regions and countries where companies should have concentrated on opportunities for cardiac biomarker testing market growth in the coming future?
Related Reports
Cardiac Monitoring System Market
Cardiac Monitoring System Market Research Report provides comprehensive insights into the Cardiac Monitoring System Market Size, Share, Key Companies, Competitive Analysis.
Cardiac Insufficiency Epidemiology
DelveInsight’s “Cardiac Insufficiency Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Cardiac Insufficiency epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Cardiac Insufficiency Pipeline
“Cardiac Insufficiency Pipeline Insight, 2022” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Cardiac Insufficiency market.
“Cardiac Amyloidosis Pipeline Insight, 2022” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Cardiac Amyloidosis market
Latest Healthcare Research Reports by Delveinsight
CAR-T Pipeline | Hyperphosphatemia Market | Primary Ciliary Dyskinesia Market | Liquid Biopsy in Cancer Diagnostics Market | HDAC Inhibitors Market | Blood Purification Devices Market | Anastomotic Leak Devices Market | Blastomycosis Market | Pigment Epithelial Detachment Market | Familial Lipoprotein Lipase Deficiency Pipeline | Cardiogenic Shock Market | Systemic Sclerosis-associated Interstitial Lung Disease Market | Vulvar Cancer Market | Artificial Disc Market | Small lymphocytic lymphoma Market | Phenylketonuria Market | Friedreich’s Ataxia Market | Temporomandibular Disorders Market | Myopia Progression Market | NK Cell Therapy- Market
Related Blogs by DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Get in touch with our team to get more detailed insights into how the MedTech Market is expected to evolve in the coming years and to formulate innovative business solutions, at MedTech Consulting Solutions
Contact Us
Yash Bhardwaj
+1(919)321-6187
More Stories
Top Advanced Gadgets You Need to Know About
Cutting-Edge Gadgets: What’s New and Advanced
Advanced Gadgets to Watch Out for This Year